RE:RE:Newsfdesloges wrote: With a prevalence of < 1:="" 1,000,000,="" as="" will="" obviously="" not="" be="" the="" future="" cash="" cow="" fueling="" any="" earning="" growth="" for="" pli.="" but="" it="" is="" highly="" strategic="" both="" because="" it="" touches="" so="" many="" organs="" that="" it="" could="" turn="" out="" in="" the="" greatest="" anti-fibrotic="" show="" case="" in="" humans="" that="" a="" pharma="" could="" dream="" to="" boast="" at="" regulatory="" agencies,="" and="" precisely="" because="" its="" prevalence="" is="" so="" small="" that="" the="" pivotal="" clinical="" trial="" will="" most="" likely="" ends="" up="" small="" and="">
That will not only benefit Prometic, but the cohorts of suffering patients, not only AS ones but all others which share fibrotic organs with AS, which will see acceleration of a drug easing improving or curing their conditions.
Meanwhile, AS offers a second, relatively rapid, opportunity for PLI to obtain a pediatric voucher in the not so distant future. Which could further accelerate 4050 advancement for a larger indication or provide non dilutive cash inflow to finance PLI prodigious pipeline. And my guts tells me it's not gonna be the last...
:-)
FD
Okay, Fdesloges you just mowed my grass.... LOL!
https://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/RarePediatricDiseasePriorityVoucherProgram/default.htm
That was my thought as well - opportunity is clear to me for a SECOND Priority Review Voucher.